Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 764

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 764
---
generativedisorders such as Parkinson’s and Alzheimer’s disease. This license agreement represents a potentially leading next -generation, first -in-class, oral, dual orexin receptor agonist platform that is expected to address high unmet medical needs and has shown promising results in pre -clinicalin vitro assays. NLS has plans to initiate proof -of-conceptpreclinical development in the second half of 2024, subject to sufficient funding. The DOXA platform, consisting of over 300 compounds, bridges the present to the future treatment of sleep disorders as well as other neuro -degenerativedisorders. Orexin receptor pathways play vital regulatory roles in many physiological processes and studies have shown that orexin receptor pathways are involved in pathological processes of neurological diseases such as obesity, narcolepsy, depression, ischemic stroke, drug addiction and Alzheimer’s disease. These new compounds, in addition to the Company’s current pipeline, including Mazindol ER for the treatment of narcolepsy, NLS -4focused on idiopathic hypersomnia, long -COVIDand chronic fatigue syndrome, and NLS -11, addressing Kleine -LevinSyndrome and neurodegenerative diseases, will further complement and strengthen our sleep franchise. NLS will be uniquely positioned to hold the key to unlock the challenges associated with rare sleep disorders now and in the future. Orexin receptor pathways play vital regulatory roles in many physiological processes and studies have shown that orexin receptor pathways are involved in pathological processes of neurological diseases such as narcolepsy, depression, ischemic stroke, drug addiction, and Alzheimer’s disease. The Agreement NLS will pay Aexon Labs an upfront payment of $30,000 for the option exclusivity and $170,000 upon execution of the definitive agreement to exercise the option. In addition, Aexon Labs will receive 15% of all proceeds earned by NLS in any future sub -licensingagreements. Other than that, the Aexon Agreement includes several milestone royalty payments to Aexon, as follows: •Milestone payment on termination of first Proof -of-Conceptstudy in OX1R/OX2R KO mice model of narcolepsy: US $100,000 •Milestone payment on issuance of the first Patent Granted in the US that covers the Licensed Product: US $300,000 •Milestone payment on issuance of the second Patent Granted in the US that covers the Licensed Product: US $150,000

| Moore Financial Consulting |

Annex E-39